A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 5.4 USD -4.59% Market Closed
Market Cap: 196.6m USD

Armata Pharmaceuticals Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Armata Pharmaceuticals Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Research & Development
-$29.8m
CAGR 3-Years
-3%
CAGR 5-Years
-24%
CAGR 10-Years
-20%
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
195.4m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
2.81 USD
Overvaluation 48%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Research & Development?
Research & Development
-29.8m USD

Based on the financial report for Jun 30, 2025, Armata Pharmaceuticals Inc's Research & Development amounts to -29.8m USD.

What is Armata Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-20%

Over the last year, the Research & Development growth was 8%. The average annual Research & Development growth rates for Armata Pharmaceuticals Inc have been -3% over the past three years , -24% over the past five years , and -20% over the past ten years .

Back to Top